rta-408 and Mitochondrial-Diseases

Mitochondrial diseases are a clinically and genetically heterogeneous group of disorders that result from dysfunction of the mitochondrial oxidative phosphorylation due to molecular defects in genes encoding mitochondrial proteins. Despite the advances in molecular and biochemical methodologies leading to better understanding of the etiology and mechanism of these diseases, there are still no satisfactory therapies available for mitochondrial disorders. Treatment for mitochondrial diseases remains largely symptomatic and does not significantly alter the course of the disease. Based on limited number of clinical trials, several agents aiming at enhancing mitochondrial function or treating the consequences of mitochondrial dysfunction have been used. Several agents are currently being evaluated for mitochondrial diseases. Therapeutic strategies for mitochondrial diseases include the use of agents enhancing electron transfer chain function (coenzyme Q

Topics: Animals; Antioxidants; Arginine; Cardiolipins; Catechin; Clinical Trials as Topic; Electron Transport; Genetic Therapy; Humans; Liver Transplantation; Mice; Mitochondria; Mitochondrial Diseases; Nitric Oxide; Oxidative Phosphorylation; Triterpenes